Cancer Center Support Grant

整体 项目总结/摘要！ 耶鲁大学癌症中心（YCC）作为NCI指定的综合性癌症中心已经有43年的历史了， 建立了一个强大的传统，高影响力的癌症研究和深厚的文化交流， 合作，团结286基础，翻译，人口和临床科学家代表所有生物医学 学科YCC为这些调查人员提供了一套支持核心和强大的协作 机会和资源。通过方案内和方案间的合作， YCC是了解和预防癌症，早期发现癌症，并管理癌症治疗更多 准确和有效。七个研究项目是YCC的核心，每个项目都由一个 基础科学家与临床/转化科学家合作，以促进跨学科研究和 耶鲁科学从实验室走向临床此外，YCC还支持和管理共享 提供独特专业知识和支持技术的资源，丰富范围并加快 每个研究项目的进展。YCC基础设施进一步实现了突破性的临床试验， 利用耶鲁大学的科学，并结合新的设计和生物标志物评估，以优化患者 选择，定义治疗抗性，并告知新的治疗方法。整体癌症资金（直接 成本）从2012年的5820万美元增加到2017年的8800万美元，增加了51%，其中包括从1780万美元增加到2350万美元 直接成本（Direct Cost）。YCC拥有两个NCI SPORE赠款，一个UM 1，U10，多个P01，多个多- 研究员R 01赠款，并在两个SU 2C梦之队奖的领导。此外，在当前 在融资周期中，YCC利用了590万美元，反映了CCSG发展基金和机构支持， 推进新的研究和合作，导致5560万美元的新的校外资金-9倍的回报， 投资在同一时期，介入治疗试验增加了82%，从471增加到859， 早期治疗试验（试点，I，I-II）的应计费用增加了三倍，现在占总数的44% 治疗累积。同样重要的是，YCC已经扩大并投资于寻求 在个人、机构和政策层面影响癌症不平等和我们集水区的需求。 在接下来的五年里，YCC将继续开发各种举措和资源，以促进创新， 合作，卓越和协同作用，以最大限度地发挥耶鲁大学的人才和专业知识的影响， 了解、预防和治疗癌症！

OVERALL PROJECT SUMMARY/ABSTRACT! Now in its 43rd year as an NCI-Designated Comprehensive Cancer Center, Yale Cancer Center (YCC) has established a strong tradition of high-impact cancer research and a deep culture of communication and collaboration that unites 286 basic, translational, population, and clinical scientists representing all biomedical disciplines. YCC arms these investigators with a suite of enabling cores and powerful collaborative opportunities and resources. Through intra- and inter-programmatic collaboration, the overarching goals of YCC are to understand and prevent cancer, detect cancer early, and manage cancer treatment more accurately and effectively. The seven Research Programs are the heart of YCC, and each program is led by a basic scientist in partnership with a clinical/translational scientist to foster transdisciplinary research and the advancement of Yale science from the bench to the clinic. In addition, YCC supports and manages Shared Resources that provide unique expertise and enabling technologies that enrich the scope and expedite progress of each Research Program. YCC infrastructure further enables ground-breaking clinical trials that capitalize on Yale science and incorporate novel designs and biomarker assessments to optimize patient selection, define treatment resistance, and inform new therapeutic approaches. Overall cancer funding (direct costs) has increased 51% from $58.2M in 2012 to $88M in 2017, including an increase from $17.8M to $23.5M in NCI funding (direct costs). YCC holds two NCI SPORE grants, a UM1, U10, multiple P01s, numerous multi- investigator R01 grants, and leadership in two SU2C Dream Team awards. Additionally, during the current funding cycle, YCC leveraged $5.9M, reflecting CCSG Developmental Funds and institutional support, to advance new research and collaborations, resulting in $55.6M in new extramural funding - a 9-fold return on investment. During the same period, accrual to interventional treatment trials increased 82%, from 471 to 859, and accruals to early-phase treatment trials (pilot, I, I-II) increased three-fold, now representing 44% of total treatment accruals. No less important, YCC has expanded and invested in initiatives and research that seeks to impact cancer inequities and the needs of our catchment area at an individual, institutional, and policy level. Over the next five years, YCC will continue to develop initiatives and resources to foster innovation, collaboration, excellence and synergy to maximize the impact of Yale’s talent and expertise on the understanding, prevention and treatment of cancer.!